Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Goodwill and Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-lived Intangible Assets, Gross	$ 50,920	$ 43,620
Finite-lived Intangible Assets, Accumulated Amortization	(17,419)	(13,767)
Finite-lived Intangible Assets, Net Carrying Value	$ 33,501	29,853
CLIA Lab [Member]
Finite-lived Intangible Asset, Useful Life (Years)	2 years 3 months 19 days
Finite-lived Intangible Assets, Gross	$ 609	609
Asuragen Acquisition [Member] \| Thyroid [Member]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 8,519	8,519
RedPath Acquisition [Member] \| Pancreas Test [Member]
Finite-lived Intangible Asset, Useful Life (Years)	7 years
Finite-lived Intangible Assets, Gross	$ 16,141	16,141
RedPath Acquisition [Member] \| Barrett's Test [Member]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 18,351	18,351
BioPharma Acquisition [Member] \| Trademarks [Member]
Finite-lived Intangible Asset, Useful Life (Years)	10 years
Finite-lived Intangible Assets, Gross	$ 1,600
BioPharma Acquisition [Member] \| Customer Relationships [Member]
Finite-lived Intangible Asset, Useful Life (Years)	8 years
Finite-lived Intangible Assets, Gross	$ 5,700